Research Article1 November 1993free access Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha and -gamma signal transduction pathways. M. Müller M. Müller Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author C. Laxton C. Laxton Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author J. Briscoe J. Briscoe Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author C. Schindler C. Schindler Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author T. Improta T. Improta Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author J.E. Darnell Jr J.E. Darnell Jr Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author G.R. Stark G.R. Stark Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author I.M. Kerr I.M. Kerr Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author M. Müller M. Müller Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author C. Laxton C. Laxton Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author J. Briscoe J. Briscoe Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author C. Schindler C. Schindler Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author T. Improta T. Improta Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author J.E. Darnell Jr J.E. Darnell Jr Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author G.R. Stark G.R. Stark Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author I.M. Kerr I.M. Kerr Imperial Cancer Research Fund Laboratories, London, UK. Search for more papers by this author Author Information M. Müller1, C. Laxton1, J. Briscoe1, C. Schindler1, T. Improta1, J.E. Darnell1, G.R. Stark1 and I.M. Kerr1 1Imperial Cancer Research Fund Laboratories, London, UK. The EMBO Journal (1993)12:4221-4228https://doi.org/10.1002/j.1460-2075.1993.tb06106.x PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Mutants in complementation group U3, completely defective in the response of all genes tested to interferons (IFNs) alpha and gamma, do not express the 91 and 84 kDa polypeptide components of interferon-stimulated gene factor 3 (ISGF3), a transcription factor known to play a primary role in the IFN-alpha response pathway. The 91 and 84 kDa polypeptides are products of a single gene. They result from differential splicing and differ only in a 38 amino acid extension at the C-terminus of the 91 kDa polypeptide. Complementation of U3 mutants with cDNA constructs expressing the 91 kDa product at levels comparable to those observed in induced wild-type cells completely restored the response to both IFN-alpha and -gamma and the ability to form ISGF3. Complementation with the 84 kDa component similarly restored the ability to form ISGF3 and, albeit to a lower level, the IFN-alpha response of all genes tested so far. It failed, however, to restore the IFN-gamma response of any gene analysed. The precise nature of the DNA motifs and combination of factors required for the transcriptional response of all genes inducible by IFN-alpha and -gamma remains to be established. The results presented here, however, emphasize the apparent general requirement of the 91 kDa polypeptide in the primary transcriptional response to both types of IFN. Previous ArticleNext Article Volume 12Issue 111 November 1993In this issue RelatedDetailsLoading ...

Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha and -gamma signal transduction pathways.